Research programme: anticancer antibodies - AbGenomicsAlternative Names: AbGn-100; AbGn-107; AbGn-108; AbGn-109; AbGn-110; AbGn-150; Antibody-100; Antibody-107; Antibody-150; Antibody-8
Latest Information Update: 18 Sep 2016
At a glance
- Originator AbGenomics Corporation
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer